In the treatment of recurrent ER-positive and Her2-negative breast cancer patients, several guidelines including NCCN and ABC320 recommend endocrine therapy with or without targeted therapy to be the preferred treatment option. This evidence concerns the gene ERBB2 and breast carcinoma.